Patent US4683200A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4683200A Expired / Lapsed US ⏱️ 0.0 years remaining

Monoclonal antibody to human cancer antigen and method for producing same

Assignee: Nippon Kayaku Co Ltd
•
Filing: 1985-05-09
•
Granted: 1987-07-28
•
Expires: 2005-05-09
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Disclosed herein is a monoclonal antibody of the IgM class which reacts with a glycoprotein antigen having a molecular weight by gel filtration of 1,000,000 or higher, the antigenic determinant to be recognized being a sugar chain with a sialic acid residue at the end thereof. The monoclonal antibody has the following characteristics: (1) a reactivity with human cancers of stomach, large intestine, pancreas, breast, lung, biliary duct, uterus and esophagus; (2) a reactivity with normal human submaxillary gland, proximal renal tubule, bronchial gland, squamous epithelial corneum, pancreatic Langerhans' islands, liver cell membrane and duodenal gland; (3) a reactivity with human intestinal metaplastic gastric mucosa; and (4) a non-reactivity with normal human prostate gland, biliary duct and pancreatic duct. Also provided in the invention is a method for production of monoclonal antibodies. The method comprises administering or implanting cancer cells or tissue to an animal having no thymus, propagating the cells or tissue in the animal, administering T cells or both T cells and B cells to the animal, taking antibody-producing B cells from the animal, fusing the B cells with myeloma cells, selecting fused cells producing an antibody against the cancer cells or tissue, cloning the fused cells, and culturing the cloned fused cell.

Inventors

  • 👤 Setsuo Hirohashi
  • 👤 Yukio Shimosato
  • 👤 Masahiko Watanabe

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 18:27
CPC Classifications
C; C12; C12N; C12N5/00; C12N5/10; C12N5/12; C12N5/16; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3046; C07K16/3015; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S530/00; Y10S530/863; Y10S530/864

Claims Analysis

Total Claims: 4
Claim 1
Independent Claim 121 words
A method for production of a monoclonal antibody which binds to human cancer cells or human cancer tissue comprising the steps of: administering or implanting human cancer cells or human cancer tissue to a murine having no thymus, propagating the cells or tissue in the murine having no thymus, administering murine T cells or both murine T cells and murine B cells to the murine having no thymus, taking antibody-producing B cells from the murine having no thymus, fusing said antibody-producing B cells with murine myeloma cells to form hybridoma cells, selecting hybridoma cells producing an antibody which binds to the human cancer cells or human cancer tissue, cloning the hybridoma cells, culturing the cloned hybridoma cells, and recovering said antibody.
Claim 2
Independent Claim 121 words
A method for production of a monoclonal antibody which binds to human cancer cells or human cancer tissue comprising the steps of: administering or implanting human cancer cells or human cancer tissue to a murine having no thymus, propagating the cells or tissue in the murine having no thymus, administering murine T cells or both murine T cells and murine B cells to the murine having no thymus, taking antibody-producing B cells from the murine having no thymus, fusing said antibody-producing B cells with murine myeloma cells to form hybridoma cells, selecting hybridoma cells producing an antibody which binds to the human cancer cells or human cancer tissue, cloning the hybridoma cells, culturing the cloned hybridoma cells, and recovering said antibody.
Claim 3
Dependent Claim 23 words
The method of claim 1, wherein the murine having no thymus is a mouse and the myeloma cells are derived from a mouse.
Claim 4
Dependent Claim 21 words
The method of claim 1, wherein the murine having no thymus is a nude mouse and the myeloma cells are P3-X63-Ag8-U1.

References Cited (Backward Citations)

US4172124A Cited
US4349528A Cited
US4584268A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-07-27 1991-01-26 1991-07-28 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-07-27 1995-01-26 1995-07-28 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-07-27 1999-01-26 1999-07-28 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag